HD-OPM Archive

Ezetimibe: the low-cost add-on

How ezetimibe blocks cholesterol absorption, what trials and registries show when it is added to a statin, where it is (and is not) supported as a stand-alone drug, and how the group's admins think about using it.

15 min read49 group posts cited48 studies discussed3 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Ezetimibe lowers LDL-C by roughly 18-20% on its own and by a further 21-30% when added to a statin, by blocking cholesterol absorption in the small intestine.1
  • In the 2026 FLOWPROMOTE trial (104 people, 18 months), rosuvastatin 40 mg plus ezetimibe 10 mg brought LDL to about 42.5 mg/dL and shrank total coronary plaque about 21%, versus LDL 69.5 mg/dL and about 14% with atorvastatin 40 mg.2
  • In Ez-PAVE (3,048 people with ASCVD), an LDL target below 55 mg/dL reached with statin plus ezetimibe cut major events 33% (6.6% vs 9.7%) compared with a target below 70 mg/dL over 3 years.3
  • No randomized trial has shown that ezetimibe alone lowers heart attack or stroke risk, so the admins warn against swapping a statin for ezetimibe on its own.4
  • A moderate-intensity statin plus ezetimibe can match a high-intensity statin on LDL lowering with fewer muscle symptoms in people aged 70 and older.5
  • Reports linking ezetimibe to lower dementia or liver-cancer risk come from databases and genetics, not from trials of those outcomes, and remain preliminary.67
In this summary
  1. What ezetimibe is and how it works
  2. What the evidence shows
  3. Nuances, controversies and common misconceptions
  4. What this means for you
  5. Frequently asked questions
  6. The evidence behind this summary

Ezetimibe is an oral, once-daily cholesterol-lowering drug that works in the gut rather than the liver. It stops much of the cholesterol in food and bile from being absorbed into the bloodstream, which lowers LDL cholesterol (LDL-C, the cholesterol carried in "bad cholesterol" particles that build up in artery walls). On its own it lowers LDL-C by roughly a fifth; added to a statin it gives a meaningful extra drop.1

The group's central message is that ezetimibe is best understood as the first, cheapest and best-tolerated add-on when a statin alone does not bring LDL low enough. The 2025 ESC/EAS dyslipidaemia guideline update, as summarised in a shared graphic, calls it the first-line oral add-on, with injectable PCSK9 drugs and inclisiran reserved for later steps in very-high-risk patients.8 Recent randomized trials, notably Ez-PAVE and FLOWPROMOTE, have strengthened the case for lower LDL targets reached with statin plus ezetimibe.39

The group is just as clear about the limits. Ezetimibe's proven outcome benefit comes from trials where it was added to a statin; it has not been shown to prevent heart attacks or strokes by itself.4 The sections below explain how it works, what the evidence shows, where the evidence is thin, and what the admins suggest discussing with your doctor.

18–20%average LDL-C drop with ezetimibe on its own1
21–30%further LDL-C drop when it is added to a statin1
33%fewer major events in Ez-PAVE with an LDL target below 55 versus below 70 mg/dL3
21.1%shrinkage of total coronary plaque in 18 months on rosuvastatin plus ezetimibe in FLOWPROMOTE2

What ezetimibe is and how it works

Ezetimibe inhibits cholesterol absorption in the small intestine.1 Statins work in a different place: they reduce cholesterol production in the liver. A shared FLOWPROMOTE explainer puts the two side by side, describing rosuvastatin as reducing cholesterol production in the liver while ezetimibe blocks absorption in the small intestine, so that the two together lower LDL further than either alone.10

A quick reference post by Gokhan (compiled from Google AI Overviews, which he says he spot-checked) gives these typical effects.1

  • Alone: LDL-C down about 15-25%, with an average of about 18-20%.
  • Added to a statin: a further 21-30% reduction in LDL-C.
  • ApoB (the count of atherogenic particles) down roughly 17-20% on monotherapy.
  • A modest rise in HDL-C and a modest fall in triglycerides.

The same 2025 ESC/EAS summary lists ezetimibe at about 20% LDL-C reduction, compared with about 23% for bempedoic acid alone (about 38% together with ezetimibe) and about 50-60% for PCSK9 antibodies.8 A separate post lists the main alternatives for people who cannot tolerate statins: ezetimibe, bempedoic acid, inclisiran, Repatha and Praluent.11

Ezetimibe is the gentlest add-onTypical LDL-C reduction from baseline for each add-on, as summarised from the 2025 ESC/EAS dyslipidaemia guideline update
Ezetimibeabout 20%
Bempedoic acidabout 23%
Bempedoic acid + ezetimibeabout 38%
PCSK9 antibodies50–60%
Approximate figures from a shared graphic; individual responses vary. Source: 8
Show data
Value
Ezetimibeabout 20%
Bempedoic acidabout 23%
Bempedoic acid + ezetimibeabout 38%
PCSK9 antibodies50–60%

Dosing and tolerability

Ezetimibe is usually taken daily. Its elimination half-life of about 22 hours means less frequent dosing can still work. In a small 2008 study from The American Journal of Cardiology, 33 patients (94% of whom had been put on ezetimibe because of muscle pain, raised liver enzymes or gut intolerance with other lipid drugs) took it three times a week. Over about 58 days, total cholesterol fell 15% and LDL-C fell 20% (about 30 mg/dL); 85% tolerated it and 48% reached their LDL goal.12 This was a small, short, uncontrolled study.

On personal experience, Gokhan reports that he did poorly on atorvastatin at any dose, was fine on rosuvastatin, and later added ezetimibe. He found combined LDL lowering with ezetimibe and then Repatha felt good, though he labels this anecdote and speculation rather than evidence.13 In another post he describes hesitating over low-dose ezetimibe before reconsidering it to approach an LDL near 50 mg/dL with his cardiologist's support.14 He also notes that on rosuvastatin 5 mg plus ezetimibe 10 mg his LDL (90, then 63 mg/dL) was not very different from low-dose rosuvastatin alone, a reminder that individual responses vary.15

What the evidence shows

Outcome evidence for statin plus ezetimibe

Gokhan's evidence digest collects several lines of data on adding ezetimibe or other non-statin drugs to a statin.16

  • A meta-analysis of 15 randomized trials (123,785 patients) of intensified lipid lowering (ezetimibe, bempedoic acid or PCSK9 inhibitors) added to statins found 19% fewer cardiovascular events than statin monotherapy (OR 0.81), with lower odds of heart attack (OR 0.81) and ischemic stroke (OR 0.77). All-cause mortality was not improved (OR 0.99), even in studies with at least 3 years of follow-up.16
  • In a Canadian primary-prevention study of 67,884 people, the combination of a statin and ezetimibe was compared with a high-intensity statin and was linked to lower all-cause death (HR 0.85) and stroke (HR 0.86), with no difference in heart attack or revascularization.16
  • In a Finnish registry of 57,505 people after a heart attack, early ezetimibe use was associated with lower all-cause mortality (adjusted HR 0.77). Only 3.7% had started ezetimibe at 90 days and 13.4% at 5 years, and 43.6% discontinued it during follow-up.16
  • In 264 STEMI patients, rosuvastatin 40 mg plus ezetimibe 10 mg reached an LDL below 55 mg/dL in 90% versus 47.9% on rosuvastatin alone.16
Adding a non-statin drug cut events, not deathsIntensified lipid lowering (ezetimibe, bempedoic acid or PCSK9 inhibitors) added to a statin versus statin alone, meta-analysis of 15 randomized trials, 123,785 patients
interval clear of 1interval includes 1 (no clear difference)95% confidence interval
Cardiovascular events0.81 (0.75–0.86)
Heart attack0.81 (0.74–0.89)
Ischemic stroke0.77 (0.70–0.84)
All-cause mortality0.99 (0.93–1.04)
Source: 16
Show data
Odds ratio95% CI
Cardiovascular events0.810.75–0.86
Heart attack0.810.74–0.89
Ischemic stroke0.770.70–0.84
All-cause mortality0.990.93–1.04

The registry and cohort findings are observational and can be shaped by who gets prescribed what. The digest itself also notes that the meta-analysis showed no mortality benefit. A shared news report, filed under the title "Statin + ezetimibe for high risk prevention," likewise concluded that blocked-artery patients should get a statin plus ezetimibe straight away rather than a statin alone, which it said could prevent thousands of deaths a year, but the post gives no numbers.17 A separate post by Louis, quoting a group member's summary, mentions the IMPROVE-IT trial (ezetimibe plus simvastatin) as showing a 2% absolute risk reduction in heart attack, while cautioning that the broader mortality trends it discusses are correlation, not causation.18

Ez-PAVE: how low should LDL go?

Ez-PAVE, published in the New England Journal of Medicine, randomized 3,048 people with atherosclerotic cardiovascular disease to an LDL target below 55 mg/dL (1.4 mmol/L) or below 70 mg/dL (1.8 mmol/L) and followed them for 3 years.3 The 70 mg/dL group was managed with statins; the 55 mg/dL group with statin plus ezetimibe.19

  • The primary composite (cardiovascular death, heart attack, stroke, revascularisation or hospitalisation for unstable angina) occurred in 6.6% versus 9.7%, a hazard ratio of 0.67 (95% CI 0.52-0.86).3
  • Non-fatal heart attack was cut by more than half and revascularisation fell 37%; safety was reported as equivalent.319
  • The shared write-up notes that fewer than 25% of eligible patients reach an LDL below 55 mg/dL, fewer than 10% receive ezetimibe and around 1% receive a PCSK9 inhibitor.3
Ez-PAVE primary composite endpoint (cardiovascular death, heart attack, stroke, revascularisation or unstable angina) at 3 years: 6.6% with the LDL target below 55 mg/dL versus 9.7% with the target below 70 mg/dL, hazard ratio 0.67. From the slides shared in the group.
Ez-PAVE primary composite endpoint (cardiovascular death, heart attack, stroke, revascularisation or unstable angina) at 3 years: 6.6% with the LDL target below 55 mg/dL versus 9.7% with the target below 70 mg/dL, hazard ratio 0.67. From the slides shared in the group.3

Louis frames it as "lower LDL" against "even lower LDL" in people who were all already treated, and argues it undercuts the view that LDL does not matter.19 A Joel Kahn comment shared by Louis says the study supports "the lower, the longer, the better" and that routinely adding ezetimibe is a smart path, though the post gives no study details.20

FLOWPROMOTE: plaque regression

FLOWPROMOTE (JAMA Cardiology, October 2026) studied 104 statin-naive adults in Denmark with stable coronary disease and more than 50% narrowing. Plaque was measured by coronary CT angiography at baseline, 9 and 18 months. One group took atorvastatin 40 mg; the other took rosuvastatin 40 mg plus ezetimibe 10 mg.910

Outcome at 18 monthsAtorvastatin 40 mgRosuvastatin 40 mg + ezetimibe 10 mg
Achieved LDL-Cabout 69.5 mg/dLabout 42.5 mg/dL
Total plaque volumeabout -13.6%about -21.1%
Non-calcified (soft) plaqueabout -20.0%about -28.2%

These figures are from posts quoting the paper.221 One post gives baseline LDL as about 120 to 70 versus 127 to 42 mg/dL, a total plaque difference of about 31 cubic millimetres, and soft plaque shrinking in 39 of 51 versus 51 of 52 participants.22 Other posts report regression in 98% versus 77% for non-calcified plaque, and 90% of the lower-LDL group for total plaque.223 The percentages differ slightly between posts, so check the paper for exact values.

The trial also found a linear relationship between achieved LDL and the amount of regression, which Louis reads as further support that LDL is causal in atherosclerosis.23 Calcified plaque rose in both groups, which the posts interpret as soft plaque hardening and stabilising.2122

Caveats stated in the posts are worth keeping in mind. FLOWPROMOTE was designed as an imaging study, not a trial of heart attacks or strokes.922 The comparison also changed two things at once (a different statin plus the addition of ezetimibe), so on its own it cannot separate the effect of the drug from the effect of the lower LDL it produced. A shared review cited by Louis reports that each 1-point drop in percent atheroma volume was associated with about 19% lower odds of major cardiovascular events, but the post stresses these are associations, not proof.2

Other imaging trials

Louis shares a summary of imaging trials by group member Daniel Chong. It lists PRECISE-IVUS (2015), in which ezetimibe was linked to a 1.4% fall in percent atheroma volume with regression in 78% of patients, and ZEUS (2014), in which adding ezetimibe in diabetic acute coronary syndrome shrank plaque 13.9% versus 5.1% with a statin alone.24 Gokhan's ranking of plaque interventions says at least six IVUS trials of adding ezetimibe showed numerically greater regression (-2.9% to -13.9% total atheroma volume), though not all reached statistical significance.25

A chart from a 2022 JACC review, shared by Louis, plots LDL-C against change in total plaque volume across trials of statins, PCSK9 inhibitors, ezetimibe and other drugs. Louis reads it as showing regression starting once LDL-C falls below roughly 90 mg/dL.2627 He lists six statin trials with 5% to 17% reversal in total plaque, driven by soft plaque.2829 Louis also lists ezetimibe among the LDL-lowering drugs in his collection of at least six plaque-reversal strategies.30

Nuances, controversies and common misconceptions

Ezetimibe alone is not proven to prevent heart attacks

Louis warns against stopping a statin in favour of ezetimibe: no randomized trial has shown ezetimibe by itself lowers the risk of heart attack and stroke, which is why most cardiologists add it to statins rather than substituting it.4 The guideline-based picture is the same: statins first, ezetimibe added if the goal is not reached.31 For people who truly cannot take statins, ezetimibe is one of the listed alternatives, usually judged by its LDL effect.1112

Combination instead of a higher statin dose

Several posts discuss pairing a moderate-intensity statin with ezetimibe rather than increasing the statin.

  • A JAMA Cardiology paper shared by Gokhan found that a moderate-intensity statin plus ezetimibe gave similar major-event outcomes to a high-intensity statin in ASCVD, with greater LDL lowering, better tolerance and less new diabetes.32
  • A NEJM clinician summary reports that in people aged 70 and older, this combination lowered LDL similarly to a high-intensity statin with significantly fewer muscle symptoms.5
  • Gokhan's digest cites a systematic review of 8 studies (40,236 patients) in secondary prevention in which the combination was linked to lower cardiovascular and all-cause mortality and fewer muscle-related adverse events than a high-intensity statin.16
From the JAMA Cardiology paper Gokhan shared: new-onset diabetes, starting diabetes medication, and stopping or reducing therapy were all less common with the alternative strategy (moderate-intensity statin plus ezetimibe) than with a high-intensity statin.
From the JAMA Cardiology paper Gokhan shared: new-onset diabetes, starting diabetes medication, and stopping or reducing therapy were all less common with the alternative strategy (moderate-intensity statin plus ezetimibe) than with a high-intensity statin.32

LDL targets differ by risk

A 2023 JAHA review, summarised by Gokhan, suggests at least a 50% LDL-C reduction and a goal below 70 mg/dL for high-risk patients, and below 55 mg/dL (or below 40 mg/dL after recurrent events on statins) for very-high-risk patients. It suggests considering ezetimibe and/or a PCSK9 inhibitor when this is not reached on maximally tolerated statins.31 Gokhan has also argued that benefit depends on both how low and how long LDL is lowered, and estimates about 60% lifetime risk reduction from a 70-point drop sustained for 30 years, noting that effects at very low levels are unknown.33 This estimate was read from a chart and is his own projection.

The JAHA 2023 review's scheme: statin intensity and non-statin therapy (ezetimibe, PCSK9 inhibitors, bempedoic acid) step up from primary prevention to plaque progression to an established cardiovascular event, with LDL-C goals of below 100, 70 and 55 mg/dL.
The JAHA 2023 review's scheme: statin intensity and non-statin therapy (ezetimibe, PCSK9 inhibitors, bempedoic acid) step up from primary prevention to plaque progression to an established cardiovascular event, with LDL-C goals of below 100, 70 and 55 mg/dL.31

Does a rising calcium score mean it is not working?

Posts on FLOWPROMOTE point out that a calcium score only sees calcified plaque. On a statin, plaque tends to pick up calcium as it hardens, so a higher score does not by itself mean the treatment failed. How fast it rose and the LDL level matter more; an older study linked a score rising over 15% a year to higher first heart attack risk.22

Inflammation, brain and cancer reports

  • Inflammation. A pooled analysis of placebo-controlled trials found ezetimibe added to a statin gave a significant extra 10% reduction in CRP, while on its own it gave a non-significant 6%.34 Louis cites a meta-analysis listing average hsCRP falls of 17.3% for statins and 3.2% for ezetimibe.35 A Cardiovascular Research meta-analysis concluded that ezetimibe, statins, bempedoic acid and omega-3 lower CRP independently of LDL-C reduction.36 Louis also notes that statins, especially with ezetimibe, lower Lp-PLA2, a plaque-specific inflammation marker.37
  • Dementia. A 2024 Aging Biology paper analysing clinical databases (nearly 950,000 older adults in one report) found much lower Alzheimer's and related dementia incidence among ezetimibe users (reported as 86% lower, or over sevenfold) plus effects on protein aggregation in lab-grown neurons.63839 It is an observational association and the researchers call for further studies.38 Louis also shares a brief post saying ezetimibe seems to reduce amyloid injury, with no study cited.4041 Separately, a Mendelian randomization study of over a million people linked genetic variants that mimic ezetimibe (NPC1L1) to 82% lower dementia per ~40 mg/dL lower non-HDL cholesterol (statin-like variants: 76%).4243 Louis also explains that ezetimibe acts on blood cholesterol and does not change cholesterol production in the brain.44
  • Liver cancer. A UK case-control study of 3,719 cases and 14,876 controls linked cholesterol absorption inhibitors to 31% lower odds of liver cancer (statins 35%); the post states this is an association, not proof, and should not be a reason to start a drug.745
  • Diabetes. Posts on glucose note a small rise in new diabetes with intensive statin treatment. A review shared by Gokhan lists ezetimibe among options that limit glycemic harm.46 A Gemini-assisted post shared by Louis, however, argues that genetic proxies for ezetimibe's target (NPC1L1) also show a modest rise in diabetes risk per unit of LDL lowered, suggesting a link to LDL lowering itself rather than to one drug.47
  • Lp(a). Louis shares an explainer saying that across 147 trials, statins, ezetimibe, fibrates and fish oil had no effect on lipoprotein(a), a genetically set LDL-like particle.48
Ezetimibe barely moves hsCRP on its ownAverage reduction in hsCRP (an inflammation marker) by drug class, as listed by Louis from a meta-analysis
Bempedoic acid20%
Statins17.3%
Fish oil12.8%
Fibrates10.3%
PCSK9 inhibitors6%
Ezetimibe3.2%
Averages across different trials; part of the effect reflects lower LDL, which is itself inflammatory. Source: 35
Show data
Value
Bempedoic acid20%
Statins17.3%
Fish oil12.8%
Fibrates10.3%
PCSK9 inhibitors6%
Ezetimibe3.2%

What this means for you

These points reflect the group's discussion and are not personal medical advice.

  • If LDL is still above goal on a statin, the admins' framing is that ezetimibe is the natural first add-on to discuss with your doctor.831
  • The strongest direct outcome evidence is for adding ezetimibe to a statin to reach lower targets (for example below 55 mg/dL in very-high-risk people).3
  • If a high-intensity statin causes muscle symptoms, the evidence shared suggests a moderate statin plus ezetimibe is a reasonable option to raise with your doctor, particularly in older adults.532
  • Stopping a statin to use ezetimibe alone is not supported by outcome trials.4
  • Do not treat a rising calcium score on treatment as automatic failure; ask your doctor to interpret it alongside LDL and imaging.22
  • Ezetimibe is also paired with newer agents; for example, a combination tablet of obicetrapib with ezetimibe was approved in the EU in 2026, with company-reported LDL falls of about 50% versus placebo.49
  • Treat reports on dementia or cancer as hypotheses, not reasons to start the drug.738

Frequently asked questions

How much will ezetimibe lower my LDL?

About 18-20% on its own, and a further 21-30% when added to a statin, according to the reference post.1 Individual results vary; one admin saw little difference between low-dose rosuvastatin alone and with ezetimibe.15

Can I take ezetimibe instead of a statin?

Louis says no randomized trial has shown ezetimibe alone lowers heart attacks or strokes, so replacing a statin is a "big risk" in his words.4 For genuine statin intolerance, ezetimibe is a listed alternative, and a small study found thrice-weekly dosing lowered LDL 20%.1112

Does lower LDL really give better results than "good enough"?

In Ez-PAVE, going below 55 mg/dL rather than 70 mg/dL cut major events by 33% over 3 years, and in FLOWPROMOTE lower achieved LDL went with more plaque regression.323

Does ezetimibe cause side effects?

The shared studies mostly report good tolerance: 85% tolerated it in the thrice-weekly study, and Ez-PAVE reported equivalent safety.312 A meta-analysis in the digest found no significant difference in adverse events between moderate statin plus ezetimibe and high-intensity statins.16

Will ezetimibe protect against dementia?

Maybe, but this is not established. The evidence is database association and genetics.642 Lipophilic statins such as atorvastatin cross into the brain, whereas ezetimibe does not affect brain cholesterol.44

The evidence behind this summary48 studies · 4 meta-analyses · 21 trials · 3 MR · 5 observational

The 49 group posts cited above discuss 48 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 4Randomized trials 21Mendelian randomization 3Observational studies 5Reviews & guidelines 6Other sources 9

Strongest evidence discussed

All 48 studies and sources
Sources from the group (49)
  1. Ezetimibe lowers LDL-C about 18-20% alone and a further 21-30% on top of a statin Gokhan Can · Sep 24, 2025 · Facebook
  2. FLOWPROMOTE: rosuvastatin plus ezetimibe shrank total coronary plaque 21% in 18 months Louis Nervegna · Nov 14, 2026 · Facebook
  3. Ez-PAVE: LDL target below 55 mg/dL cut major events 33% versus below 70 mg/dL Louis Nervegna · May 29, 2026 · Facebook
  4. No randomized trial shows ezetimibe alone lowers heart attack or stroke risk Louis Nervegna · Aug 13, 2026 · Facebook
  5. Moderate statin plus ezetimibe matched high-intensity LDL drop with less myalgia at 70+ Louis Nervegna · May 13, 2025 · Facebook
  6. Ezetimibe use linked to 86% lower Alzheimer's and dementia risk in database analysis Louis Nervegna · Oct 19, 2026 · Facebook
  7. Statin use linked to 35% lower odds of liver cancer in UK database study Louis Nervegna · Sep 15, 2026 · Facebook
  8. 2025 ESC/EAS update: where ezetimibe, bempedoic acid, PCSK9 drugs and inclisiran fit Louis Nervegna · Oct 19, 2025 · Facebook
  9. FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months Louis Nervegna · Oct 31, 2026 · Facebook
  10. FLOWPROMOTE: rosuvastatin plus ezetimibe vs atorvastatin for plaque regression Louis Nervegna · Nov 07, 2026 · Facebook
  11. Statin-intolerant? Options include ezetimibe, bempedoic acid, inclisiran, PCSK9 antibodies Louis Nervegna · May 30, 2026 · Facebook
  12. Thrice-weekly ezetimibe cut LDL-C 20% in 33 statin-intolerant patients Gokhan Can · Sep 22, 2025 · Facebook
  13. Admin's experience adding ezetimibe, pitavastatin and Repatha after statin intolerance Gokhan Can · Jan 08, 2026 · Facebook
  14. Friend's heart attack at 48 prompts reconsideration of LDL 70 and low-dose ezetimibe Gokhan Can · Sep 07, 2025 · Facebook
  15. Admin asks cardiologist about rosuvastatin raising insulin, and pitavastatin plus PCSK9i Gokhan Can · Dec 30, 2025 · Facebook
  16. Ezetimibe beyond statins: fewer events, no mortality gain in trials, registry benefits Gokhan Can · Nov 07, 2024 · Facebook
  17. Starting statin plus ezetimibe together may save more lives in blocked-artery patients Gokhan Can · Mar 23, 2025 · Facebook
  18. Heart disease deaths fell almost 5x since 1950 as LDL targets tightened Louis Nervegna · Nov 13, 2024 · Facebook
  19. EZ-PAVE: LDL target <55 vs <70 cut major CV events by 33% in over 3,000 patients Louis Nervegna · Mar 31, 2026 · Facebook
  20. New study: lower LDL for longer is better, supporting routine ezetimibe add-on (Joel Kahn) Louis Nervegna · Mar 29, 2026 · Facebook
  21. FLOWPROMOTE: combination therapy shrank soft plaque 28% vs 20% with LDL near 42 vs 70 Louis Nervegna · Oct 31, 2026 · Facebook
  22. A rising calcium score on a statin does not mean it failed, per FLOWPROMOTE details Louis Nervegna · Nov 08, 2026 · Facebook
  23. FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43 Louis Nervegna · Oct 31, 2026 · Facebook
  24. Evidence that plaque can shrink: CENIT, PRECISE-IVUS, ZEUS, EVAPORATE and GLAGOV Louis Nervegna · Jun 25, 2025 · Facebook
  25. Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence Gokhan Can · May 18, 2024 · Facebook
  26. Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs Louis Nervegna · Aug 12, 2025 · Facebook
  27. Six randomized trials show statins reduce total plaque volume 5-17% from baseline Louis Nervegna · Mar 02, 2026 · Facebook
  28. Six RCTs show statins reverse total plaque volume by 5% to 17% Louis Nervegna · Aug 25, 2026 · Facebook
  29. Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL Louis Nervegna · Oct 31, 2026 · Facebook
  30. At least six strategies have reversed plaque in randomized trials Louis Nervegna · Aug 12, 2026 · Facebook
  31. Evolving LDL-C management (JAHA 2023): risk categories, thresholds and treatment goals Gokhan Can · Nov 25, 2023 · Facebook
  32. Moderate statin plus ezetimibe matched high-intensity statins on MACE with lower LDL Gokhan Can · Nov 24, 2024 · Facebook
  33. The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction Gokhan Can · Nov 20, 2023 · Facebook
  34. Adding ezetimibe to a statin lowers CRP by an extra 10% in pooled trials Gokhan Can · Nov 09, 2024 · Facebook
  35. Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP Louis Nervegna · Dec 28, 2025 · Facebook
  36. Meta-analysis: statins, bempedoic acid, ezetimibe and omega-3 lower CRP independent of LDL Gokhan Can · Feb 19, 2024 · Facebook
  37. Statins, especially with ezetimibe, lower Lp-PLA2, a plaque-specific inflammation marker Louis Nervegna · Jun 22, 2025 · Facebook
  38. Ezetimibe linked to lower Alzheimer's risk in database analysis and lab experiments Gokhan Can · Aug 07, 2024 · Facebook
  39. Ezetimibe linked to over 7-fold lower Alzheimer's and related dementia risk Gokhan Can · Jul 12, 2024 · Facebook
  40. Ezetimibe may reduce dementia risk by lowering amyloid Louis Nervegna · Feb 12, 2026 · Facebook
  41. Ezetimibe associated with lower dementia risk, possibly by reducing amyloid injury Louis Nervegna · Mar 16, 2026 · Facebook
  42. Statin- and ezetimibe-like gene variants linked to 76-82% lower dementia risk per 40 mg/dL Louis Nervegna · Aug 28, 2026 · Facebook
  43. Mendelian randomization in 1 million people: statin-like genetics cut dementia risk 76-82% Gokhan Can · Nov 06, 2025 · Facebook
  44. Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't Louis Nervegna · Oct 18, 2025 · Facebook
  45. Ezetimibe-type absorption inhibitors linked to 31% lower liver cancer odds; statins 35% Louis Nervegna · Aug 01, 2024 · Facebook
  46. Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist Gokhan Can · Nov 26, 2025 · Facebook
  47. Genetics suggest statins' small diabetes risk is tied to LDL lowering (Gemini-assisted) Louis Nervegna · Sep 07, 2026 · Facebook
  48. Lp(a) explained: an LDL particle with a tail, genetic, unaffected by standard drugs Louis Nervegna · Sep 03, 2026 · Facebook
  49. Obicetrapib gets first approval worldwide in the EU, lowering LDL up to 40-50% Louis Nervegna · Sep 21, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary